Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 41Myeloproliferative Disorders 30Polycythemia Vera 28Leukemia, Myeloid, Acute 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Leukemia 17Myelodysplastic Syndromes 15Thrombocythemia, Essential 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Neoplasms 9Multiple Myeloma 9Graft vs Host Disease 9Breast Neoplasms 9Pancreatic Neoplasms 8Leukemia, Myelomonocytic, Chronic 8Recurrence 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, Non-Hodgkin 6Leukemia, Lymphocytic, Chronic, B-Cell 6Hematologic Neoplasms 6Prostatic Neoplasms 5Lymphoma, T-Cell 5Lymphoma 5Leukemia, Myeloid, Chronic-Phase 5Hodgkin Disease 5Hematologic Diseases 5Colorectal Neoplasms 5Thrombocytosis 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Carcinoma, Non-Small-Cell Lung 4

Interventions

Fulvestrant 10Alpelisib 7Everolimus 6Cetuximab 6Letrozole 4serabelisib 3ribociclib 3pembrolizumab 3palbociclib 3duvelisib 3berzosertib 3Paclitaxel 3PX-866 3NVP-BKM120 3Irinotecan 3sapanisertib 2parsaclisib 2olaparib 2binimetinib 2Topotecan 2Gemcitabine 2Carboplatin 2volagidemab 1venetoclax 1tivozanib 1tipifarnib 1tanezumab 1talazoparib 1sotorasib 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × ruxolitinib × Clear all
NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Incyte Corporation

Phase 2 Terminated
74 enrolled 40 charts
Myeloid

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡